Spyre Therapeutics (SYRE) Return on Capital Employed (2016 - 2026)
Spyre Therapeutics (SYRE) posted Return on Capital Employed of 29.41% for Q1 2026, up 18.26% on a QoQ basis from 35.98% in Q4 2025, and up 1194.0% year-over-year from 2.27% in Q1 2025.
Spyre Therapeutics (SYRE) Return on Capital Employed (2016 - 2026) Analysis & Trends
Spyre Therapeutics' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 29.41% for Q1 2026.
- Quarterly Return on Capital Employed rose 1194.0% year-over-year to 29.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.41% (up 1194.0% YoY) and the FY2025 annual result came in at 33.03%, up 1650.0% from the prior year.
- Return on Capital Employed was 29.41% for Q1 2026 at Spyre Therapeutics, up from 35.98% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 256.36% in Q2 2023 and bottomed at 160.99% in Q1 2023.
- A 5-year average of 56.44% and a median of 52.08% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 36714 bps — and 2024, when it plunged 29188 bps.
- Spyre Therapeutics' Return on Capital Employed stood at 127.11% in 2022, then advanced by 21 bps to 99.88% in 2023, then jumped by 55 bps to 45.27% in 2024, then climbed by 21 bps to 35.98% in 2025, then increased by 18 bps to 29.41% in 2026.
- Business Quant data shows SYRE's Return on Capital Employed at 29.41% in Q1 2026, 35.98% in Q4 2025, and 44.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -29.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.41% |
| Dec 31, 2025 | -35.98% |
| Sep 30, 2025 | -44.94% |
| Jun 30, 2025 | -45.02% |
| Mar 31, 2025 | -41.35% |
| Dec 31, 2024 | -45.27% |
| Sep 30, 2024 | -52.08% |
| Jun 30, 2024 | -35.52% |
| Mar 31, 2024 | -72.94% |
| Dec 31, 2023 | -99.88% |
| Sep 30, 2023 | -119.40% |
| Jun 30, 2023 | 256.36% |
| Mar 31, 2023 | -160.99% |
| Dec 31, 2022 | -127.11% |
| Sep 30, 2022 | -105.65% |
| Jun 30, 2022 | -110.78% |
| Mar 31, 2022 | -89.57% |
| Dec 31, 2021 | -66.08% |
| Sep 30, 2021 | -57.81% |
| Jun 30, 2021 | -48.86% |